HRP20110890T1 - Dihidročalkon sličan aspalatinu, ekstrakti iz nefermentiranog crvenog grma i postupci njegovog dobivanja - Google Patents
Dihidročalkon sličan aspalatinu, ekstrakti iz nefermentiranog crvenog grma i postupci njegovog dobivanja Download PDFInfo
- Publication number
- HRP20110890T1 HRP20110890T1 HR20110890T HRP20110890T HRP20110890T1 HR P20110890 T1 HRP20110890 T1 HR P20110890T1 HR 20110890 T HR20110890 T HR 20110890T HR P20110890 T HRP20110890 T HR P20110890T HR P20110890 T1 HRP20110890 T1 HR P20110890T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- extract
- formula
- accordance
- acid
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract 14
- 240000006914 Aspalathus linearis Species 0.000 title claims abstract 5
- 238000002360 preparation method Methods 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 4
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 title 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 13
- 235000015872 dietary supplement Nutrition 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 238000013375 chromatographic separation Methods 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- AAWZDTNXLSGCEK-WYWMIBKRSA-N (-)-quinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-N 0.000 claims 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 235000003884 Aspalathus contaminatus Nutrition 0.000 claims 1
- 235000012984 Aspalathus linearis Nutrition 0.000 claims 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 235000004883 caffeic acid Nutrition 0.000 claims 1
- 229940074360 caffeic acid Drugs 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 235000001368 chlorogenic acid Nutrition 0.000 claims 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims 1
- 229940074393 chlorogenic acid Drugs 0.000 claims 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims 1
- 239000007859 condensation product Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000001785 ferulic acid Nutrition 0.000 claims 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims 1
- 229940114124 ferulic acid Drugs 0.000 claims 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 239000000174 gluconic acid Substances 0.000 claims 1
- 235000012208 gluconic acid Nutrition 0.000 claims 1
- 229950006191 gluconic acid Drugs 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims 1
- AKGDIVKDYFDRLS-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-[3-[2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2h-chromen-4-yl]-2,4,6-trihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]propan-1-one Chemical compound OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C3=C(O)C=C(O)C=C3OC(C2O)C=2C=C(O)C(O)=CC=2)=C(O)C(C(=O)CCC=2C=C(O)C(O)=CC=2)=C1O AKGDIVKDYFDRLS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj, naznačen time što je spoj formule Ii njegove farmaceutski prihvatljive soli, derivati, i to kondenzacijski produkti spoja formule I s ferulinskom kiselinom, kinskom kiselinom, kavenom kiselinom, glukonskom kiselinom ili klorogenom kiselinom, te esteri, i to esteri s mravljom kiselinom, octenom kiselinom, propionskom kiselinom, glutarnom kiselinom, vinskom kiselinom i jantarnom kiselina. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Spoj, naznačen time što je spoj formule I
[image]
i njegove farmaceutski prihvatljive soli, derivati, i to kondenzacijski produkti spoja formule I s ferulinskom kiselinom, kinskom kiselinom, kavenom kiselinom, glukonskom kiselinom ili klorogenom kiselinom, te esteri, i to esteri s mravljom kiselinom, octenom kiselinom, propionskom kiselinom, glutarnom kiselinom, vinskom kiselinom i jantarnom kiselina.
2. Ekstrakt crvenog grma (Rooibos, Aspalathus linearis), koji sadrži spoj formule I u skladu s patentnim zahtjevom 1, naznačen time što se ekstrakt crvenog grma dobiva iz nefermentiranog crvenog grma.
3. Ekstrakt crvenog grma u skladu s patentnim zahtjevom 2, naznačen time što mu je sadržaj spoja formule I najmanje 1,0%, težinski.
4. Ekstrakt crvenog grma u skladu s patentnim zahtjevom 3, naznačen time što mu je sadržaj spoja formule I najmanje 2%, težinski.
5. Ekstrakt crvenog grma u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time što mu je ukupni sadržaj flavonoida najmanje 20%, težinski.
6. Postupak dobivanja spoja formule I u skladu s patentnim zahtjevom 1 i ekstrakta crvenog grma u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time što
– osušeni i usitnjeni, nefermentirani sirovi materijal crvenog grma se ekstrahira ekstrakcijskim sredstvom, koje je alkohol i/ili voda, kroz prethodno zadano vrijeme ekstrakcije, na temperaturi do 90 °C, osobito do 60 °C,
– ekstrakt se filtrira, te otpari do suhog pod sniženim tlakom,
naznačen time što je ekstrakcijsko sredstvo 10 do 60% (vol/vol) alkohola, a ostatak je voda.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što se pomnije pročišćavanje provodi u najmanje jednom koraku kromatografskog razdvajanja.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time što je korak kromatografskog razdvajanja gel-permeacijska kromatografija.
9. Prehrambeni dodatak, naznačen time što sadrži najmanje 1 mg spoja formule I u skladu s patentnim zahtjevom 1 po g prehrambenog dodatka.
10. Prehrambeni dodatak, naznačen time što sadrži ekstrakt crvenog grma u skladu s patentnim zahtjevima 2 do 5, u količini od najmanje 10 mg/g prehrambenog dodatka.
11. Prehrambeni dodatak u skladu s patentnim zahtjevom 9 ili 10, naznačen time što ga se pripravlja na takav način da sadrži najmanje 1 mg spoja formule I u skladu s patentnim zahtjevom 1, osobito najmanje 5 mg spoja formule I u skladu s patentnim zahtjevom 1, na osnovu dnevne doze.
12. Medikament, naznačen time što sadrži spoj formule I u skladu s patentnim zahtjevom 1 ili ekstrakt crvenog grma u skladu s bilo kojim od patentnih zahtjeva 2 do 5.
13. Upotreba spojeva u skladu s patentnim zahtjevom 1 ili ekstrakta crvenog grma u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačena time što su spojevi ili ekstrakt namijenjeni pripravi medikamenta za sprječavanje i/ili liječenje neuroloških i psihičkih poremećaja središnjeg živčanog sustava.
14. Upotreba u skladu s patentnim zahtjevom 13, naznačena time što su neurološki i psihički poremećaji središnjeg živčanog sustava demencije, Parkinsonova bolest, depresija i bol.
15. Upotreba u skladu s patentnim zahtjevom 14, naznačena time što je poremećaj središnjeg živčanog sustava Alzheimerova bolest ili staračka demencija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07020728A EP2053050B1 (de) | 2007-10-23 | 2007-10-23 | Aspalathin-ähnliches Dihydrochalcon und Verfahren zur Herstellung |
| EP08801873.4A EP2069334B2 (de) | 2007-10-23 | 2008-09-05 | Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung |
| PCT/EP2008/007279 WO2009052895A1 (de) | 2007-10-23 | 2008-09-05 | Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20110890T1 true HRP20110890T1 (hr) | 2011-12-31 |
| HRP20110890T4 HRP20110890T4 (en) | 2015-02-27 |
Family
ID=38805677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20110890AT HRP20110890T4 (en) | 2007-10-23 | 2011-11-28 | Aspalathin-like dihydrochalcone, extracts from unfermented rooibos and process for preparation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100222423A1 (hr) |
| EP (2) | EP2053050B1 (hr) |
| JP (1) | JP5527900B2 (hr) |
| AT (2) | ATE522524T1 (hr) |
| DK (2) | DK2053050T3 (hr) |
| ES (2) | ES2372203T3 (hr) |
| HR (1) | HRP20110890T4 (hr) |
| PL (2) | PL2053050T3 (hr) |
| PT (2) | PT2053050E (hr) |
| WO (1) | WO2009052895A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE518544T1 (de) | 2007-03-12 | 2011-08-15 | Zadec Aps | Rotbusch-extrakt gegen diabetes |
| WO2016072522A1 (ja) * | 2014-11-06 | 2016-05-12 | 国立大学法人 長崎大学 | 新規アルツハイマー病治療薬 |
| JP6735224B2 (ja) * | 2016-01-28 | 2020-08-05 | 花王株式会社 | アストロサイトのグルコース代謝活性化剤 |
| JP7244273B2 (ja) * | 2018-12-27 | 2023-03-22 | 株式会社 伊藤園 | ルイボス茶飲料の製造方法 |
| CN109932448A (zh) * | 2019-03-29 | 2019-06-25 | 完美（广东）日用品有限公司 | 一种线叶金雀花及其制品中有效成分的含量测定方法 |
| CN115104730A (zh) * | 2022-06-28 | 2022-09-27 | 北京姿美堂生物技术股份有限公司 | 一种改善睡眠的组合物、线叶金雀花-芦笋睡眠改善液、茶粉的制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2895298B2 (ja) * | 1991-12-27 | 1999-05-24 | 株式会社ユニエ | 活性酸素消去・除去剤 |
| JPH05246866A (ja) * | 1992-03-06 | 1993-09-24 | Ruibosuteii Japan:Kk | 脳代謝促進・脳機能改善剤 |
| JPH11116429A (ja) † | 1997-10-13 | 1999-04-27 | Mikimoto Pharmaceut Co Ltd | 化粧品原料および化粧品 |
| JP2001316239A (ja) * | 2000-05-10 | 2001-11-13 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
| KR100421233B1 (ko) * | 2001-09-10 | 2004-03-11 | 한국원자력연구소 | 식품, 의약품 및 화장품 제조용 천연물의 색도 개선 방법 및 이의 방법에 의해 색도가 개선된 천연물 추출물 |
| ZA200303674B (en) * | 2002-02-20 | 2005-04-26 | Benedict Technology Holdings P | Antioxidant composition. |
| JP4637491B2 (ja) * | 2004-03-01 | 2011-02-23 | 株式会社東洋発酵 | 抗アレルギー用組成物 |
| DE102004052800B4 (de) * | 2004-10-30 | 2017-02-23 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Verbesserte Trägerformulierungen |
| DE102005004438B4 (de) * | 2005-01-31 | 2007-12-20 | Raps Gmbh & Co. Kg | Rooibos-Extrakt mit erhöhtem Aspalathingehalt, Verfahren zur Herstellung eines solchen Rooibos-Extraktes und kosmetisches Mittel enthaltend einen solchen Rooibos-Extrakt |
| JP2007161661A (ja) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | アドバンスド・グリケーション・エンドプロダクツを分解するための化粧料とその製造法 |
| ATE518544T1 (de) † | 2007-03-12 | 2011-08-15 | Zadec Aps | Rotbusch-extrakt gegen diabetes |
-
2007
- 2007-10-23 PL PL07020728T patent/PL2053050T3/pl unknown
- 2007-10-23 AT AT07020728T patent/ATE522524T1/de active
- 2007-10-23 DK DK07020728.7T patent/DK2053050T3/da active
- 2007-10-23 ES ES07020728T patent/ES2372203T3/es active Active
- 2007-10-23 EP EP07020728A patent/EP2053050B1/de not_active Not-in-force
- 2007-10-23 PT PT07020728T patent/PT2053050E/pt unknown
-
2008
- 2008-09-05 PL PL08801873T patent/PL2069334T5/pl unknown
- 2008-09-05 DK DK08801873.4T patent/DK2069334T4/da active
- 2008-09-05 EP EP08801873.4A patent/EP2069334B2/de not_active Not-in-force
- 2008-09-05 US US12/739,280 patent/US20100222423A1/en not_active Abandoned
- 2008-09-05 AT AT08801873T patent/ATE533763T1/de active
- 2008-09-05 JP JP2010530290A patent/JP5527900B2/ja not_active Expired - Fee Related
- 2008-09-05 WO PCT/EP2008/007279 patent/WO2009052895A1/de active Application Filing
- 2008-09-05 PT PT08801873T patent/PT2069334E/pt unknown
- 2008-09-05 ES ES08801873.4T patent/ES2373509T5/es active Active
-
2011
- 2011-11-28 HR HRP20110890AT patent/HRP20110890T4/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2069334E (pt) | 2011-12-30 |
| EP2069334A1 (de) | 2009-06-17 |
| DK2053050T3 (da) | 2011-11-21 |
| ES2373509T5 (es) | 2015-02-16 |
| HRP20110890T4 (en) | 2015-02-27 |
| PL2053050T3 (pl) | 2012-01-31 |
| EP2053050B1 (de) | 2011-08-31 |
| ATE522524T1 (de) | 2011-09-15 |
| ATE533763T1 (de) | 2011-12-15 |
| PL2069334T3 (pl) | 2012-04-30 |
| JP2011501755A (ja) | 2011-01-13 |
| PL2069334T5 (pl) | 2015-06-30 |
| DK2069334T4 (da) | 2014-12-08 |
| JP5527900B2 (ja) | 2014-06-25 |
| ES2372203T3 (es) | 2012-01-17 |
| PT2053050E (pt) | 2011-12-09 |
| WO2009052895A1 (de) | 2009-04-30 |
| EP2053050A1 (de) | 2009-04-29 |
| DK2069334T3 (da) | 2012-01-23 |
| ES2373509T3 (es) | 2012-02-06 |
| US20100222423A1 (en) | 2010-09-02 |
| EP2069334B1 (de) | 2011-11-16 |
| EP2069334B2 (de) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110890T1 (hr) | Dihidročalkon sličan aspalatinu, ekstrakti iz nefermentiranog crvenog grma i postupci njegovog dobivanja | |
| JP6059756B2 (ja) | 新規ボスウェリア低極性ゴム樹脂抽出物およびその相乗的組成物 | |
| AU2014324608B2 (en) | Nutraceutical compositon for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation | |
| MX2008012065A (es) | Extractos y metodos que comprenden especies de te verde. | |
| CA2920601C (en) | Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same | |
| US20190085007A1 (en) | 4-methylcatechol Derivatives and Uses Thereof | |
| US20080319052A1 (en) | Lipopexia Inhibitor and Food or Beverage | |
| JP5528025B2 (ja) | Ｔｇ合成抑制剤 | |
| KR102225574B1 (ko) | 고본추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방, 치료, 또는 개선용 조성물 | |
| KR20190047873A (ko) | 특정 성분 함량이 증가된 차 추출물을 포함하는 지방대사 이상의 예방 및 개선용 조성물 | |
| JP2011501755A5 (hr) | ||
| KR20210002378A (ko) | 송화분 추출물을 유효성분으로 포함하는 간 보호용 조성물 | |
| Saito et al. | Green tea extract-patents and diversity of uses | |
| US20100124578A1 (en) | Appetite-suppressing weight management composition | |
| KR101392188B1 (ko) | 육두구 추출물 또는 이로부터 분리된 리그난계 화합물을 함유하는 시르투인 활성화에 의해 매개되는 질환의 예방 또는 치료용 조성물 | |
| JP2009185004A (ja) | メタボリック・シンドローム改善剤 | |
| US20220175866A1 (en) | Enzymatically treated catechin product with increased contents of gallic acid, epicatechin, and epigallocatechin and method for producing same | |
| WO2009103164A1 (en) | Anti-obesity compositions comprising orlistat and various natural products | |
| CN111757749A (zh) | 用于预防、改善或治疗肥胖和代谢性疾病的包含桃花和荷叶的组合提取物的组合物 | |
| KR100951696B1 (ko) | 모노아민산화효소 억제제에 의해 매개되는 질병의 예방또는 치료용 조성물 | |
| JP2015097511A (ja) | ポリフェノール誘導体の製造方法、ポリフェノール誘導体を含有する飲食品および医薬品組成物 | |
| JP6861139B2 (ja) | セロトニン代謝抑制剤、飲食品組成物、及び、医薬品 | |
| KR102335690B1 (ko) | 신규한 트리테르펜 사포닌 유도체 및 이의 용도 | |
| JP6152735B2 (ja) | 白色脂肪細胞の褐色様脂肪細胞分化誘導剤組成物 | |
| US9511035B2 (en) | Java ginger extract and manufacturing method |